Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis

Therapeutic Drug Monitoring

Volumn 12, Issue 5, 1990, Pages 419-426

  Destache, Christopher J ^a,c   Meyer, Sharon K ^b   Bittner, Marvin J ^d   Hermann, Kenneth G ^c  

^a UKMC   (United States)

^b AMI Saint Joseph Hospital ^*  (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Clinical pharmacokinetic service; Cost benefit analysis

Indexed keywords

AMINOGLYCOSIDE;

ADULT; AGED; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMIC ASPECT; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

AMIKACIN; AMINOGLYCOSIDES; BACTERIAL INFECTIONS; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; FEMALE; GENTAMICINS; GRAM-NEGATIVE BACTERIA; HUMAN; LENGTH OF STAY; MALE; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; TOBRAMYCIN;

EID: 0025007982     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/00007691-199009000-00003     Document Type: Article

References (24)

1. Levy G. Applied pharmacokinetics: a prospectus. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 2nd ed. Spokane, WA: Applied Therapeutics, Inc., 1986:i-xxi.
2. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 2nd ed. Spokane, WA: Applied Therapeutics, Inc., 1986:370.
3. Gyselynch AM, Forrey A, Cutler R. Pharmacokinetics of gentamicin: distribution of plasma and renal clearance. J Infect Dis 1971;124:S70-6.
4. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21:407-11.
5. Bootman JL, Wertheimer AI, Zaske DE, et al. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979;68:267-72.
6. Kimelblatt BJ, Bradbury K, Chodoff L, et al. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm 1986;43:1205-9.
7. Zaske DE, Bootman JL, Solem LB, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery 1982;91:142-9.
8. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia: re-evaluation of clincal features and treatment in 612 patients. Am J Med 1980;68:344-55.
9. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;194:443-8.
10. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis1987;155:93-9.
11. Destache CJ, Meyer SK, Ortmeier BG, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. DICP: The Annuals of Pharmacotherapy 1989;23:33-7.
12. Jelliffe RW, Jelliffe SM. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. Math Biosci 1972;14:17-24.
13. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med1985;13:818-29.
14. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, IL: Drug Intelligence Publications, 1979:59-63.
15. Jelliffe RW. Clinical applications for pharmacokinetics and control therapy: planning, monitoring, and adjusting dosage regimens of aminoglycosides, lidocaine, digitoxin, and digoxin. In: Maronde R, ed. Topics of clinical pharmacology and therapeutics. New York: Springer Verlag, 1986:26-82.
16. Sheiner LB, Rosenberg B, Melmon K. Modeling of individual pharmacokinetics for computer-aided drug dosage. Corn-put Biomed Res 1972;5:441-59.
17. Hurst AK, Iseri KT, Gill MA, et al. Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis. Clin Pharm 1987;6:234-8.
18. Nie NH, Hull CH, Jenkins JG, et al. Statistical package for the social sciences. 2nd ed. New York, McGraw-Hill Book Co., 1975.
19. Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986;80:1093-7.
20. McGhan WF, Rowland CR, Bootman JL. Cost-benefit and cost-effectiveness: Methodologies for evaluating innovative pharmaceutical services. Am J Hosp Pharm 1978;35:133-40.
21. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107:900-9.
22. Bootman JL, Zaske DE, Wertheimer AI, et al. Cost of individualizing aminoglycoside dosage regimens. Am J Hosp Pharm 1979;36:368-70.
23. Elenbass RE, Payne VW, Bauman JL. Influence of clinical pharmacists on the use of drug blood level tests. Am J Hosp Pharm 1980;37:61-4.
24. Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 1987;9:306-10.